Bioventus shares surge 14.79% after-hours as Q3 organic revenue grows 8%, non-GAAP earnings jump 200%, and cash flow triples.

Bioventus Inc. (BVS) surged 14.79% in after-hours trading following the release of its third-quarter earnings report, which highlighted 8.2% organic revenue growth to $138.7 million, a 200% increase in non-GAAP earnings to $0.15 per share, and a 12.9% rise in adjusted EBITDA to $26.6 million. The company reaffirmed 2025 guidance for revenue ($560–570 million) and non-GAAP EPS ($0.64–0.68), despite a 0.2% decline in reported revenue due to the prior-year divestiture of its Advanced Rehabilitation Business. Strong performance in Pain Treatments (+6.4%) and Surgical Solutions (+9.3%) offset the restorative therapies decline, while cash flow from operations jumped 192% to $30.1 million. Management emphasized disciplined cost control, product innovation (e.g., XCELL PRP System), and a new credit agreement reducing annual interest expenses by $2 million. The results exceeded analyst expectations and reinforced confidence in the company’s strategic initiatives and market positioning.